Fig. 1: GnRH Agonist Mode of Action in Pre-Menopausal Breast Cancer. | npj Breast Cancer

Fig. 1: GnRH Agonist Mode of Action in Pre-Menopausal Breast Cancer.

From: Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer

Fig. 1

(adapted from Lu et al. 2). Upon initiation of GnRH agonist therapy, it mimics endogenous LHRH and stimulates the production of FSH and LH from the pituitary, resulting in an initial surge of E2 from the ovaries. With long-term administration of GnRH agonists, the LHRH receptors are downregulated and desensitized, resulting in reduced ovarian hormone production. Abbreviations: GnRH gonadotropin-releasing hormone, LHRH luteinizing hormone-releasing hormone, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, ER estrogen receptor. Graphics used with permission under a Creative Commons Attribution 3.0 unported license from Servier Medical Art by Servier, available at smart.servier.com.

Back to article page